Video

Do Bisphosphonates Reduce Cancer Risks?

Publish date: January 6, 2012

 

SAN ANTONIO – Dr. William J. Gradishar, associate editor of The Oncology Report, discusses the conflicting results from multiple clinical trials over the last decade and whether bisphosphonates reduce cancer recurrence and metastatic risk.

Recommended Reading

Doctors, Patients Disconnected on Aromatase Inhibitor Compliance
MDedge Hematology and Oncology
Fulvestrant Adds Punch to Anastrozole for HR+ Breast Cancer
MDedge Hematology and Oncology
Imiquimod/Abraxane Combo Effective for Skin Mets
MDedge Hematology and Oncology
Less Trastuzumab Cardiotoxicity in Beta-Blocker Users
MDedge Hematology and Oncology
Pegfilgrastim Costly, Unnecessary in Some Breast Cancer Patients
MDedge Hematology and Oncology
Adjuvant Ibandronate: No Gain in Early Breast Cancer
MDedge Hematology and Oncology
Program Curbs Shoulder Morbidity Post Breast Cancer
MDedge Hematology and Oncology
Cancer Death Rates Continue to Drop
MDedge Hematology and Oncology
Community Oncology Podcast - Radiation in breast cancer
MDedge Hematology and Oncology
Retrospective Study of Patients with Metastatic Triple-Negative Breast Cancer: Survival, Health Care Utilization, and Cost
MDedge Hematology and Oncology